CN114028384A - Application of licorice isoflavane derivative in preparation of medicine for preventing, relieving or/and treating pruritus - Google Patents
Application of licorice isoflavane derivative in preparation of medicine for preventing, relieving or/and treating pruritus Download PDFInfo
- Publication number
- CN114028384A CN114028384A CN202110218633.XA CN202110218633A CN114028384A CN 114028384 A CN114028384 A CN 114028384A CN 202110218633 A CN202110218633 A CN 202110218633A CN 114028384 A CN114028384 A CN 114028384A
- Authority
- CN
- China
- Prior art keywords
- glycyrrhiza
- isoflavan
- pruritus
- trpv3
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 112
- 239000003814 drug Substances 0.000 title claims abstract description 46
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical class C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 title claims description 79
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title description 23
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 title description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 title description 7
- 229940010454 licorice Drugs 0.000 title description 7
- 238000002360 preparation method Methods 0.000 title description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 title 1
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 98
- -1 glycyrrhiza isoflavane derivative Chemical class 0.000 claims abstract description 46
- 230000036541 health Effects 0.000 claims abstract description 7
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 claims description 68
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 37
- 229960003720 enoxolone Drugs 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 102000003568 TRPV3 Human genes 0.000 abstract description 57
- 101150043371 Trpv3 gene Proteins 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 39
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 32
- 230000001154 acute effect Effects 0.000 abstract description 32
- 229940079593 drug Drugs 0.000 abstract description 24
- 230000001684 chronic effect Effects 0.000 abstract description 22
- 238000012360 testing method Methods 0.000 abstract description 20
- 229960001340 histamine Drugs 0.000 abstract description 16
- 230000003042 antagnostic effect Effects 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 11
- 230000001419 dependent effect Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000004044 response Effects 0.000 abstract description 9
- 150000002611 lead compounds Chemical class 0.000 abstract description 3
- 238000012827 research and development Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000002324 isoflavanes Nutrition 0.000 description 72
- 241000699670 Mus sp. Species 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 39
- 238000006748 scratching Methods 0.000 description 33
- 230000002393 scratching effect Effects 0.000 description 33
- 108010014211 seryl-leucyl-isoleucyl-glycyl-arginyl-leucine Proteins 0.000 description 30
- CNOKQOBEMGIIAH-JYAZKYGWSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O CNOKQOBEMGIIAH-JYAZKYGWSA-N 0.000 description 27
- 108091006146 Channels Proteins 0.000 description 22
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 19
- 206010012438 Dermatitis atopic Diseases 0.000 description 17
- 201000008937 atopic dermatitis Diseases 0.000 description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 description 16
- 108060008564 TRPV Proteins 0.000 description 16
- 102000003563 TRPV Human genes 0.000 description 16
- 235000011477 liquorice Nutrition 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000002674 ointment Substances 0.000 description 15
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 14
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 14
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 14
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 14
- 102000003566 TRPV1 Human genes 0.000 description 12
- 101150016206 Trpv1 gene Proteins 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000001890 transfection Methods 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 10
- 229960002882 calcipotriol Drugs 0.000 description 10
- 239000004378 Glycyrrhizin Substances 0.000 description 9
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 9
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 9
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 9
- 229960004949 glycyrrhizic acid Drugs 0.000 description 9
- 235000019410 glycyrrhizin Nutrition 0.000 description 9
- RTRZOHKLISMNRD-UHFFFAOYSA-N isoflavanone Chemical compound C1OC2=CC=CC=C2C(=O)C1C1=CC=CC=C1 RTRZOHKLISMNRD-UHFFFAOYSA-N 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 8
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000000465 moulding Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- DDOQBQRIEWHWBT-UHFFFAOYSA-N 2-azaniumyl-4-phosphonobutanoate Chemical compound OC(=O)C(N)CCP(O)(O)=O DDOQBQRIEWHWBT-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 6
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical group C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000633107 Homo sapiens Transient receptor potential cation channel subfamily V member 3 Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000052198 human TRPV3 Human genes 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108091005462 Cation channels Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010068842 Olmsted syndrome Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229940123223 TRPA1 agonist Drugs 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 208000024703 mutilating palmoplantar keratoderma with periorificial keratotic plaques Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000633069 Homo sapiens Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 1
- 102400001335 Mucolipin Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010070503 PAR-2 Receptor Proteins 0.000 description 1
- 102000032628 PAR-2 Receptor Human genes 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010039986 Senile pruritus Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108060008646 TRPA Proteins 0.000 description 1
- 108010036769 TRPA1 Cation Channel Proteins 0.000 description 1
- 102000012253 TRPA1 Cation Channel Human genes 0.000 description 1
- 102000027549 TRPC Human genes 0.000 description 1
- 108060008648 TRPC Proteins 0.000 description 1
- 102000027545 TRPM Human genes 0.000 description 1
- 108091008847 TRPM Proteins 0.000 description 1
- 108091008846 TRPML Proteins 0.000 description 1
- 102000027544 TRPML Human genes 0.000 description 1
- 108091008849 TRPN Proteins 0.000 description 1
- 108060009332 TRPP Proteins 0.000 description 1
- 108010004408 TRPP Cation Channels Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 102000052408 human TRPA1 Human genes 0.000 description 1
- 102000045756 human TRPV1 Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 210000002248 primary sensory neuron Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000009209 sensory transmission Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of glycyrrhiza isoflavane derivative in preparing medicines or health products for preventing, relieving or/and treating pruritus, and tests show that the glycyrrhiza isoflavane derivative is an antagonistic molecule of TRPV3, treats pruritus by taking TRPV3 as a target spot, has obvious effects on preventing, relieving and treating pruritus, and especially has obvious effects on treating acute pruritus and chronic pruritus which are not dependent on histamine; the glycyrrhiza isoflavane derivative has quick response, small toxic and side effects, good safety and good medicinal prospect for pruritus, is a novel TRPV3 antagonistic molecule, can be used as a lead compound, and is further used for research and development of TRPV3 related disease treatment medicines. The invention also provides a new medicine source for preventing, relieving and treating the pruritus cutanea.
Description
Technical Field
The invention relates to the field of medicines, relates to a medicine or health-care product for preventing, relieving and/or treating pruritus, and particularly relates to application of a natural product of a liquorice isoflavan derivative component in traditional Chinese medicine liquorice in medicines or health-care products for preventing, relieving and/or treating pruritus.
Background
The licorice isoflavane compound is a natural product derived from traditional Chinese medicine licorice, and previous researches reveal that the licorice has wide pharmacological effects, and particularly the licorice isoflavane compound has found effects of antibiosis, anticancer, antioxidation, anti-inflammation and the like. On the basis of the existing research, further excavation of the new action and the molecular mechanism behind the compound has important research and application values.
Transient receptor potential channels (TRPs) are a class of nonselective cation channels that are widely expressed in many tissues and organs and are involved in the regulation of a variety of cellular functions. TRP channels are divided into 7 subfamilies according to amino acid sequence homology: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPA (ankyrin), TRPN (NompC), TRPP (polycystin), and TRPML (mucolipin). Through mediating the transmembrane flow of intracellular and extracellular cations, TRP channels play a key role in the processes of absorption of cellular calcium ions, guidance of neuronal growth cones, growth and differentiation of keratinocytes, conduction of sensory signals and the like. More importantly, a range of human diseases, including polycystic kidney disease, skeletal developmental malformations, Olmsted syndrome, etc., have been shown to be triggered by dysfunction of TRP channels.
For the TRPV subfamily, since the first member TRPV1 was successfully cloned in 1997, the other members of the subfamily were also successively discovered and cloned. From the viewpoint of molecular sequence and structure, six member sequences of the TRPV subfamily are highly homologous and all have a molecular structure similar to that of the classical voltage-dependent potassium channel, i.e. they are tetramers assembled from 4 subunits, each of which contains 6 transmembrane regions, and the N-terminus containing the ankyrin repeat structure and the C-terminus containing the "TRP domain" located on the intracellular side. Between the 5 th and 6 th transmembrane domains there is a ring structure which defines the pore path through which the ions pass and is believed to be related to the ion selectivity of the channel. As non-selective cation channels, members of the TRPV subfamily all have a higher permselectivity for divalent cationsCa is especially indicated for middle energizer2+Ions are the most important. Because TRPV channels are regulated by temperature, pH value and a series of endogenous and exogenous ligand molecules, the TRPV channels are widely involved in the transmission of body sensory information and have the function of regulating and controlling intracellular Ca2+Balance, etc. of various important physiological functions.
The TRPV3 channel was first cloned in 2002 and found to be activated by warming (31-39 ℃). Subsequent studies have found more compounds that can activate TRPV3, including 2-APB and natural molecules such as camphor, menthol, carvacrol, etc. The TRPV3 channel is widely expressed in various tissue organs, of which various epithelial tissues are most important, including mainly the epidermis of the skin, mouth, and gastrointestinal tract. Previous studies on mice found that TRPV3 knockout mice, on the one hand, can develop temperature disturbances, abnormal curling of hair and impaired skin barrier; furthermore, after knockout of TRPV3, mice had significantly reduced scratching response in acute pruritus induced by the polypeptide SLIGRL, as well as chronic pruritus in atopic dermatitis models and xeroderma models. On the other hand, transgenic mice expressing TRPV3 function-enhancing mutants (p.g573s) show severe alopecia and skin erythema, edema, erosion, desquamation, etc., accompanied by marked spontaneous pruritic behavior. More importantly, the previous researches show that the function-enhancing mutation of the human TRPV3 can cause a rare hereditary skin disease, namely, the Olmsted syndrome, and the symptoms of the patients are intensively expressed as severe keratinization and even progressive damage of hand and foot skins, severe alopecia, pain and pruritus and the like. These studies indicate that TRPV3 plays an important role in the physiological processes of skin barrier, hair development, temperature sensing, inflammatory response, pain and itch sensory transmission, etc.; as an important target of skin drugs, especially the potential for treating pruritus, TRPV3 has become increasingly one of the TRP channels currently in the most interest. However, due to the continuing lack of effective research tools, including specific agonists and antagonists, etc., finding and developing more drug molecules that modulate TRPV3 has become a focus of common attention in order to solve more important problems related to TRPV 3.
For the functional study of ion channels, the evaluation of the effect of a compound on it has traditionally relied primarily on the detection of electrophysiological properties. The single cell patch clamp recording technology is the most widely applied electrophysiological detection technology due to its direct and sensitive advantages, and specifically, the high-impedance seal formed by the glass microelectrode and the cell membrane surface is utilized to connect the ion channel expressed on the cell membrane into the annular circuit composed of the amplifier, the electrode and the bath solution, and when different stimuli are applied, the opening and closing conditions of the ion channel are reflected according to the recorded current change in the circuit under certain manual clamping cell membrane potential.
Itching is a common unpleasant sensation that can induce a scratching response, similar to pain, but also distinguished because pain often encourages people to try to avoid touching the affected part. The generation process of the itch is similar to the sense of pain, and the itch depends on the detection of various itching-causing molecules by primary afferent neurons on nerve endings of peripheral organs such as skin and the like, external itching-causing sources, or endogenous itching-causing molecules secreted by skin cells, immune cells and the like, firstly activates primary sensory neurons to generate nerve impulses, and the nerve signals are immediately afferent to spinal cord dorsal horn and finally conducted to sensory centers of the brain to generate the itch after being relayed by neurons in the spinal cord. It is generally believed that different itch-causing agents activate different groups of sensory neurons, and that the itch responses induced by different itch-causing agents can be broadly classified into histamine-dependent and histamine-independent types, based on the response to histamine, the most common itch-causing agent. Meanwhile, according to the duration of the feeling of pruritus, the pruritus can be divided into two categories of acute pruritus and chronic pruritus, and compared with the warning significance of the acute pruritus, the chronic pruritus which is continuously weakened can be caused along with certain skin and systemic diseases, and can be caused when the body has no other obvious diseases, so that the pruritus becomes a disease which has no obvious physiological significance and is purely annoying.
As one common clinical symptom of dermatology, pruritus is accompanied with various diseases, such as atopic dermatitis, eczema, psoriasis and the like, nerve and molecular mechanisms related to histamine-dependent pruritus and histamine-independent pruritus are gradually revealed at present, so that a plurality of medicines for treating skin pruritus are developed, including antihistamine medicines mainly aiming at histamine-dependent pruritus and cooling medicines capable of transiently relieving pruritus, and the medicines have limited action range or large side effect, and itching relieving medicines aiming at histamine-independent acute pruritus and chronic pruritus are continuously lacked in clinic, so that more itching relieving medicines with brand new action mechanisms are developed, and new hope is brought to people suffering from pruritus.
Disclosure of Invention
The invention aims to provide the application of isoflavane derivatives of liquorice in preparing medicines for treating pruritus, aiming at the defects of the existing medicines for treating pruritus, in particular to the itching-relieving medicines for treating non-histamine-dependent acute pruritus and chronic pruritus and the technical defects of the medicines in application, wherein the isoflavane derivatives of liquorice are antagonistic molecules of TRPV3, take TRPV3 as a target spot, treat pruritus and have obvious treatment effect on the non-histamine-dependent acute pruritus and the chronic pruritus.
In order to achieve the purpose of the invention, the invention provides an application of a glycyrrhiza isoflavane derivative in preparing a medicine or health-care product for preventing, relieving or/and treating pruritus.
Wherein the glycyrrhiza isoflavan derivative is one or more of glycyrrhiza isoflavan formazan, glycyrrhetin or derivatives taking 3-phenylchroman as a core, or a stereoisomer and pharmaceutically acceptable salts and/or solvates thereof, and preferably glycyrrhiza isoflavan formazan and glycyrrhetin.
Wherein the structures of the isoflavan-methyl glycyrrhizae and the liquiritigenin are as follows:
by utilizing an electrophysiological patch clamp recording technology, natural product compounds from traditional Chinese medicines are tested in an HEK293T cell line over-expressing a TRPV3 channel, and the screened liquorice isoflavan-a and the liquiritigenin have the capacity of antagonizing TRPV3 in a dose-dependent manner.
Wherein the medicament consists of the glycyrrhiza isoflavan derivative and a pharmaceutically acceptable carrier.
In particular, the purity of the glycyrrhiza isoflavan derivative is more than or equal to 1 percent, and preferably more than 95 percent or 95-100 percent of pure substances.
In particular, pharmaceutically acceptable carriers are generally approved by health care professionals for this purpose and as inactive ingredients of medicaments. A compilation of pharmaceutically acceptable carriers can be found in tools such as The Handbook of Pharmaceutical excipients (Handbook of Pharmaceutical excipients, 2 nd edition, edited by A.Wade and P.J.Weller; published by American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994).
Wherein the pruritus is histamine-dependent or/and histamine-independent pruritus, preferably histamine-independent pruritus.
In particular, the pruritus is acute pruritus or/and chronic pruritus.
Wherein the medicine is in the form of tablet, capsule, pill, powder, granule, syrup, emulsion, injection, spray, gel, cream, cataplasma, and rubber patch.
In particular, the medicament is in the form of tablets, capsules, pills, powders, granules, syrups.
In another aspect, the invention provides a medicament or health product containing the glycyrrhiza isoflavan derivative for preventing, relieving or/and treating pruritus.
Wherein the glycyrrhiza isoflavan derivative is one or more of glycyrrhiza isoflavan formazan, glycyrrhetin or derivatives taking 3-phenylchroman as a core, or a stereoisomer and pharmaceutically acceptable salts and/or solvates thereof, and preferably glycyrrhiza isoflavan formazan and glycyrrhetin.
In particular, the purity of the glycyrrhiza isoflavan derivative is more than or equal to 1 percent, and preferably more than 95 percent or 95-100 percent of pure substances.
In particular, the ratio of the weight of the glycyrrhiza isoflavan derivative to the total weight of the medicament or health product is (0.01-10): 100, preferably (0.1-1): 100.
the medicine can be made into various dosage forms by methods known in the art, such as tablets, capsules, pills, powders, granules, syrups, solutions, injections, sprays, aerosols, gel types, creams, tinctures, cataplasms, rubber plasters or emplastrums, and the like.
The invention also provides a method for preventing, relieving or/and treating pruritus, which comprises the step of administering a therapeutically effective amount of the isoflavan derivatives (isoflavanone glycyrrhiza and liquiritigenin) to pruritus, wherein the therapeutically effective amount is 0.3-100 mg/kg.d, preferably 1-20 mg/kg.d, and more preferably 10 mg/kg.d.
The term "therapeutically effective amount" as used herein, unless otherwise indicated, is the amount of drug required to produce an effective effect; the "therapeutically effective amount" is adjustable and variable and ultimately determined by the medical practitioner, taking into account factors including the route of administration and the nature of the formulation, the general condition of the recipient's weight, age, etc., and the nature and severity of the condition being treated.
Compared with the prior art, the invention has the following obvious advantages:
1. the invention develops new medicinal value for known compounds of glycyrrhiza isoflavan derivatives (glycyrrhiza isoflavan formazan and glycyrrhetin), is used for preventing, relieving and treating pruritus and can be prepared into medicaments or health-care products for preventing, conditioning and/or treating pruritus, thereby developing a new field for the application of natural product compounds in traditional Chinese medicinal materials of liquorice and liquorice.
2. The glycyrrhiza isoflavan derivatives (glycyrrhiza isoflavan formazan and glycyrrhetin) have clear pharmacological action, obvious effect of preventing, relieving and treating pruritus, quick response, small toxic and side effect, good safety and good medicinal prospect.
3. The product of the invention has rich raw material sources, low price, safe clinical use, simple preparation process, small dosage and convenient use, can be prepared into various dosage forms, and is easy to popularize.
4. The glycyrrhiza isoflavan derivatives (glycyrrhiza isoflavan formazan and glycyrrhetin) are novel TRPV3 antagonistic molecules, can be used as lead compounds, and are further used for research and development of medicines for treating TRPV3 related diseases.
The invention adopts a mouse model of non-histamine-dependent acute pruritus induced by polypeptide SLIGRL, tests the ability of the isoflavanone and the liquiritigenin to inhibit the acute pruritus by counting the scratching times within 30min as a behavior detection index, and the result shows that the isoflavanone and the liquiritigenin can inhibit the acute pruritus induced by SLIGRL in a dose-dependent manner.
The ability of isoflavan-methyl glycyrrhizae and liquiritigenin to inhibit chronic pruritus is tested by taking statistics of scratching times per hour at different molding days as an inspection index by using a mouse model of atopic dermatitis chronic pruritus established by calcipotriol induction, and the result shows that the isoflavan-methyl glycyrrhizae and the liquiricidin can inhibit the chronic pruritus of a mouse model of atopic dermatitis to some extent.
The invention obtains a new antagonistic molecule based on the screening of a target molecule TRPV3, the antagonistic molecule shows the activity of inhibiting the histamine-independent acute pruritus and the chronic pruritus, and can be used as a lead compound for further research and development of pruritus treatment medicines.
Drawings
FIG. 1 is a graph of the antagonistic effect of different concentrations of Glycyrrhiza isoflavan nails on 2-APB-induced TRPV3 current, wherein A is a representative curve recording TRPV3 current changes in whole cell mode, including changes when 100 μ M2-APB stimulation was given alone, and when multiple concentrations (30, 100 and 300 μ M) of Glycyrrhiza isoflavan nails were simultaneously superimposed; b is a dose-effect relationship diagram of antagonism of TRPV3 channel by isoflavane, and is obtained by fitting and calculating S-type dose-effect curve, and IC of isoflavane50The value was 20.87. mu.M (LogIC)501.320 ± 0.128, n ═ 4-5), data for each concentration are expressed as mean ± SEM;
FIG. 2 is a graph of the antagonistic effect of different concentrations of Liquiritidine on 2-APB-induced TRPV3 current, wherein A is a representative curve of TRPV3 current changes recorded in whole cell mode, including changes when 100 μ M2-APB stimulation was given alone, and when multiple concentrations (10, 30 and 100 μ M) of Liquiritidine were simultaneously superimposed; b is the dose effect of the Liquiritidine antagonizing TRPV3 channelThe relation chart is obtained by fitting and calculating an S-type dose-effect curve, and the IC of the liquorice isoflavanone50The value was 15.24. mu.M (LogIC)501.183 ± 0.120, n ═ 5-8), data for each concentration are expressed as mean ± SEM;
FIG. 3 is a representative plot of the change in TRPV3 current recorded in the intra-membrane out-facing mode, including the current change when 100 μ M2-APB stimulation was given alone, and when different concentrations of Glycyrrhetini and Glycyrrhetini were simultaneously superimposed, wherein A is Glycyrrhetini; b is Liquiritidine; finally 10 μ M ruthenium red completely blocked the TRPV3 current.
FIG. 4 is a graph of the effects of Glycyrrhiza isoflavan A and Glycyrrhiza uralensis on TRPV1 and TRPA1 channels, respectively; wherein: A. b is a representative curve of TRPV1 current change recorded in a whole cell mode, and comprises the current change condition when the TRPV1 agonist capsaicin is singly administered and 100 mu M of glycyrrhiza isoflavan nail (A) or glycyrrhizacin (B) is simultaneously added, and finally the current can be completely blocked by the non-selective TRP channel antagonist ruthenium red; C. d is a representative curve of TRPA1 current changes recorded in a whole cell mode, including the changes when TRPA1 agonist AITC is singly administered and 100 mu M of glycyrrhiza isoflavan formazan (C) or glycyrrhizacin (D) is simultaneously added, and finally the current can be completely blocked by a non-selective TRP channel antagonist ruthenium red; E. f: a comparison graph of the blocking ability of glycyrrhiza isoflavan formazan (E) and glycyrrhetin (F) on TRPV3, TRPV1 and TRPA1 is shown. Test with unpaired Student's t,. P < 0.001. The above data are expressed as mean ± SEM, n is 4-8.
FIG. 5 shows the inhibitory effect of Glycyrrhiza isoflavan A on SLIGRL-induced acute pruritus; wherein A-C: the line graphs of the number of scratching times of mice in the experimental groups with 30, 100 and 300 μ M effects of glycyrrhiza isoflavanone and the corresponding control group without drug treatment were counted for a period of 5min, and by analysis of variance with repeated measurements, P >0.05(a-B),. P <0.01 (C); d is a bar graph of total scratching times within 30min for experimental groups with 30, 100 and 300 μ M effects of glycyrrhiza isoflavan formazan and corresponding control group mice. Test with paired Student's t, P <0.05, P <0.01, n.s.: P >0.05, each of which is expressed as mean ± SEM, n ═ 8;
FIG. 6 shows the inhibitory effect of Liquiridine on SLIGRL-induced acute pruritus; A-C: 30. the line graphs of scratching times of mice in the experimental groups with 100 and 300 mu M functions of the Liquiritidine and the corresponding control groups are counted according to a time period of 5min, and the variance analysis of repeated measurement is adopted, wherein P is greater than 0.05(A-B) and P is less than 0.05 (C); d: 30. bar graphs of total number of scratching within 30min for 100 and 300 μ M glycyrrhetin-affected experimental and corresponding control mice. Test with paired Student's t,. P <0.01, n.s.: P >0.05, each of the above data are expressed as mean ± SEM, n ═ 8;
FIG. 7 is a graph of the percent inhibition of SLIGRL-induced acute pruritus by different concentrations of Glycyrrhetini A and Glycyrrhizacetin, as well as the percent of SLIGRL acute pruritus versus wild-type for TRPV3 KO mice; the histogram is the ratio of total scratching times within 30min of mice in the experimental group and corresponding control group, on which 30, 100 and 300 μ M of actions of glycyrrhiza isoflavan a and glycyrrhetin are superimposed, and the ratio of total scratching times within 30min of TRPV3 KO mice and wild mice, all of which are expressed by mean value + -SEM, and n is 5-8.
Fig. 8 is a schematic representation of the protocol for induction of AD model mice with calcipotriol and treatment with TRPV3 antagonist, the dotted arrow above the timeline indicating the days of molding of the mouse ears with calcipotriol, the black arrow below indicating the days of applying 1% o of isoflavan or liquiritigenin to the mouse ears, and the video recording before molding and administration on days 0, 4, and 7;
fig. 9 is a calcipotriol-induced chronic pruritus response in AD model mice at different test time points; wherein:
a, C, E: respectively counting the line graphs of scratching times of mice in an experimental group and a model group as a control, wherein the experimental group is formed by overlapping 1 per mill of effects of glycyrrhiza isoflavan and glycyrrhetin on 0 th, 4 th and 7 th days; analysis of variance using repeated measurements,. P < 0.05;
b, D, F: a bar chart of the total scratching times of mice in the experimental group and the model group as a control within 60min, wherein the experimental group is formed by superposing 1 per mill of the effects of glycyrrhiza isoflavan and glycyrrhetin on the 0 th day, the 4 th day and the 7 th day respectively; the unpaired Student's t test was used to compare to the control group,. P <0.05, n.s.: P > 0.05. The data in each group are expressed as mean value + -SEM, and n is 7-8;
FIG. 10 is a bar graph of the average ear thickness of mice in the experimental group and the model group without drug treatment, wherein 1 ‰ of effects of glycyrrhiza isoflavan and glycyrrhetin are superimposed on days 0, 4, and 7; unpaired Student's t assay was used to compare to control groups,. P <0.01,. P < 0.001. The data in each group are expressed as mean value + -SEM, and n is 7-8;
FIG. 11 shows the results of observation of HEK293T cells under a fluorescence microscope after different treatments; each line corresponds to the left label, and images of a typical field of view are taken under white light (bright field), Green Fluorescence (GFP), and red fluorescence (PI staining) channels. After transient transfection of TRPV 3G 573S mutant plasmid, the HEK293T cells show GFP green fluorescence and strong red fluorescence signals (PI staining), and the number of cells with normal morphology is reduced; if 20 mu M ruthenium red is added during transfection, the green fluorescence signal of the cells is stronger, but the red fluorescence signal becomes very weak; meanwhile, when the liquorice isoflavan and the glycyrrhetinic acid with different concentrations (10 and 20 mu M) are added, red fluorescence signals are weak, and the scale is 100 mu M;
FIG. 12 shows TRPV 3G 573S mutation channel transient transfection of HEK293T cells under the same conditions, and the chemiluminescence intensity obtained by adding different concentrations (10 and 20. mu.M) of glycyrrhiza isoflavana, glycyrrhetin and ruthenamine, and cell viability without adding any antagonist, respectively, was tested; unpaired Student's t assay was used to compare P <0.01 to a control group without any added antagonist. The above data are expressed as mean ± SEM, n is 5.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
The beneficial effects of the drug of the present invention are further illustrated by the following test examples, which include pharmacodynamic tests of the drug of the present invention.
The glycyrrhiza isoflavanone is white powder, is produced by Yunnan Xili company, and has the purity of 97 percent when being measured by an area normalization method of an ultraviolet detector and an evaporative light scattering detector of two detectors of a high performance liquid chromatography. Batch number: BBP 03331;
liquiritidine: white powder, produced by Yunnan Xili corporation, has a purity of 98% as determined by an area normalization method of a high performance liquid chromatography two-detector ultraviolet detector and an evaporative light scattering detector. Batch number: BBP 03353.
The method for producing the glycyrrhiza isoflavan molecules of the present invention is not particularly limited, and those skilled in the art can produce the glycyrrhiza isoflavan molecules of the present invention based on the common general knowledge in the art or obtain the glycyrrhiza isoflavan molecules of the present invention (glycyrrhiza isoflavan-a and glycyrrhetin) on the market.
Test example 1 Effect of Glycyrrhetini flavanoid Compound on TRPV3
The effect of compounds on overexpressed human TRPV3 was assessed using the cell patch clamp method.
HEK293T cell line was purchased from ATCC center, USA, and it was inoculated in DMEM complete medium after recovery, saturated humidity and containing 5% CO2The culture was carried out in a 37 ℃ incubator.
Before transfection, HEK293T cells were seeded into 6-well plates and when the cell density reached 50-70%, the eukaryotic expression plasmid pCMV6-AC-GFP-TRPV3 (Origene, usa, cat # RG211184) containing the human TRPV3 cDNA was transfected using Lipofectamine 3000 transfection reagent.
The electrophysiological detection method adopts whole cell or membrane inside-out (inside-out) recording mode, applies HEKA EPC10 type amplifier and PatchMaster recording software, uses P-97 type microelectrode drawing instrument to draw an electrode with impedance of 3-5M omega, and records current (cell clamping potential of 0mV) with + -80 mV square wave voltage.
The method comprises the steps of placing HEK293T cells transfected with TRPV3 plasmid for 16-24h into specially prepared bath lotion (130mM NaCl,3mM HEPES,0.3mM EGTA, pH 7.4), selecting cells with good states, clean surfaces and strong green fluorescence signals, slowly moving an electrode added with internal liquid (the components of the internal liquid and the bath lotion) to slightly contact the surface of a cell membrane, slightly applying negative pressure until a high-resistance seal is formed, breaking the membrane to form a whole cell recording mode, or directly lifting the electrode after the high-resistance seal is formed, tearing off a membrane at the tip of the electrode, and forming an inner membrane facing outwards mode.
1) Under a whole-cell recording mode, gravity perfusion is carried out by using an RSC-200 rapid exchange drug delivery system, 100 mu M2-APB is firstly given to activate a TRPV3 channel, and then different concentrations (300 mu M, 100 mu M and 30 mu M) of the isoflavane A are respectively superposed; or different concentrations (100. mu.M, 30. mu.M and 10. mu.M) of Liquiridine, a significant decrease in current amplitude was observed. Wherein the current reduction range is continuously enlarged along with the increase of the concentration of the superimposed glycyrrhiza isoflavan until the glycyrrhiza isoflavan finally almost completely disappears (as shown in figure 1A); the results for glycyrrhizin were also similar, i.e. in whole cell mode, addition of glycyrrhizin reduced the 2-APB induced current and the magnitude of the current reduction was dose dependent (as in fig. 2A).
By measuring the corresponding antagonistic capacity of the glycyrrhiza isoflavan and the glycyrrhetinic acid on TRPV3 current under a plurality of concentrations and fitting by utilizing an S-type dose response curve, the method can be obtained: IC of glycyrrhiza isoflavan50Has a value of 20.87 μ M (shown in FIG. 1B), IC of Liquiritidine50The value was 15.24. mu.M (see FIG. 2B).
2) In the intra-membrane outward recording mode, i.e. recording only the current of the channel on a single membrane, it was also observed that glycyrrhiza isoflavana and glycyrrhetin were able to dose-dependently decrease the 2-APB induced current (see fig. 3), indicating that their ability to inhibit 2-APB current is not dependent on the assistance of intracellular molecules, but should act directly on the TRPV3 channel itself.
Test example 2 Effect of Glycyrrhetini flavanoid Compound on TRPV1 or TRPA1
The effect of compounds on overexpressed human TRPV1 and TRPA1 was assessed using a cell patch clamp approach.
HEK293T cell line was purchased from ATCC center, USA, and it was inoculated in DMEM complete medium after recovery, saturated humidity and containing 5% CO2The culture was carried out in a 37 ℃ incubator.
Before transfection, HEK293T cells were seeded into 6-well plates and when the cell density reached 50-70%, either eukaryotic expression plasmid pCMV6-AC-GFP-TRPV1 (Origene, usa, cat # RG217653) containing human TRPV 1cDNA or eukaryotic expression plasmid pCMV6-AC-GFP-TRPA1 (Origene, cat # RG219290) containing human TRPA1cDNA was transfected using Lipofectamine 3000 transfection reagent.
The electrophysiological detection method adopts a whole cell or membrane inside-outside recording mode, applies an HEKA EPC10 type amplifier and PatchMaster recording software, uses an electrode with the impedance of 3-5M omega drawn by a P-97 type microelectrode drawing instrument, and records current (the cell clamping potential is 0mV) by plus or minus 80mV square wave voltage.
The method comprises the steps of taking HEK293T cells transfected with TRPV1 or TRPA1 plasmids for 16-24h, placing the cells in specially prepared bath solution (130mM NaCl,3mM HEPES,0.3mM EGTA, pH 7.4), selecting the cells with better state, clean surfaces and stronger green fluorescence signals, then slowly moving an electrode added with internal liquid (the components of the electrode are the same as the bath solution) to slightly contact the surface of a cell membrane, slightly applying negative pressure until a high-resistance seal is formed, and breaking the membrane to form a whole cell recording mode.
By utilizing an electrophysiological detection method, 100 mu M of the action of isoflavane on TRPV1 agonist capsaicin or TRPA1 agonist AITC induced current is recorded in HEK293T cells over-expressing TRPV1 or TRPA1 in vitro, and as a result, the isoflavane has weak blocking effect on TRPV1 (the blocking rate is 31.9% +/-6.6%, shown in figure 4A), while almost no antagonism is observed on TRPA1 (3.3% +/-15.5%, shown in figure 4C), and the effect is remarkably lower than that of antagonism on TRPV3 (88.0% +/-7.5%, shown in figure 4E), and the results indicate that the isoflavane has better action specificity on TRPV3 channels. Similar electrophysiological test methods are utilized to detect the effect of 100 mu M of liquiritigenin on TRPV1 and TRPA1 currents, and the blocking degree of the liquiritigenin on TRPV1 and TRPA1 (TRPV 1: 52.2% + -10.1%, FIG. 4B; TRPA 1: 8.4% + -10.8%, FIG. 4D) is also obviously lower than the antagonistic degree (93.3% + -5.8%, FIG. 4F) of the liquiritigenin on TRPV3, which indicates that the liquiritigenin also has certain effect specificity on TRPV3 channels.
For the animal model of pruritus, the standard acute pruritus model adopts intradermal injection of an pruritus-inducing agent into the back of the neck of a mouse to generate pruritus reaction, and characterizes the pruritus degree by counting the scratching times within a certain time after injection, wherein one-time scratching behavior is recorded when the injection site is lifted from the hind paw of the mouse until the hind paw falls down again or is put into the mouth for licking.
Common itch-causing agents include histamine, chloroquine, 5-hydroxytryptamine, compound 48/80, and the polypeptide SLIGRL, among others. As a result of the newly published studies, mice were significantly reduced in scratching response after TRPV3 knockdown for acute pruritus induced by intradermal injection of the activator SLIGRL of PAR 2. Therefore, the SLIGRL acute itch model was chosen as a paradigm for assessing the effect of TRPV3 antagonist molecules in inhibiting acute itch effects under physiological conditions.
Test example 3 Effect of Glycyrrhiza isoflavan A on mouse acute itching model
Selecting 24 purchased 8-10 week old (20-25 g in weight, half male and female) wild type C57BL/6J mice (Schbefu (Beijing) laboratory animal science and technology Co., Ltd.), randomly dividing into 3 groups, namely, a liquorice isoflavan A high dose group (300 mu M), a middle dose group (100 mu M) and a low dose group (30 mu M), wherein 8 mice in each group are removed from the back of the neck of the mice at least 2-3 days in advance;
on the day of formal experiment, the mice are respectively put into observation boxes (15cm multiplied by 10cm) for adaptive activity for about 5 min; then, firstly, injecting 50 mul of physiological saline containing different concentrations (30 muM, 100 muM and 300 muM) of the glycyrrhiza isoflavan nail into the skin of the right ear in advance, continuously injecting 50 mul of physiological saline containing 50 mug of SLIGRL at the same position after 30min and overlapping with the physiological saline of the glycyrrhiza isoflavan nail with corresponding concentration (namely, the physiological saline contains both SLIGRL and the glycyrrhiza isoflavan nail, wherein the concentration of the glycyrrhiza isoflavan nail is respectively corresponding to the concentration during the injection in advance, namely, the SLIGRL + the glycyrrhiza isoflavan nail) so as to induce acute pruritus; immediately placing the injected mice into an observation box, keeping quiet condition, recording for 30min by a camera and looking back the video afterwards, and counting scratching behaviors with 5min as a time period.
On alternate days, 50. mu.l of physiological saline containing 0.1% DMSO (solvent) was pre-injected intradermally in the back of the left ear, as a control group (no administration), and after 30min, 50. mu.l of physiological saline containing 50. mu.g SLIGRL (also containing 0.1% DMSO) was continuously injected into the same site to induce acute pruritus; immediately placing the injected mice into an observation box, keeping quiet condition, recording for 30min by a camera and looking back the video afterwards, and counting scratching behaviors with 5min as a time period.
As a result, it was found that the mice were variously reduced in the total scratching frequency within 30min after injection of SLIGRL in the case of the additive use of 30, 100 or 300 μ M of glycyrrhiza isoflavan nail as compared with the control group without drug administration (i.e., only SLIGRL was injected on the left ear side, i.e., SLIGRL + DMSO group) (fig. 5D).
However, the difference between the 30 μ M experimental group and the control group did not reach a significant level (P. 0.1047), whereas the level of decrease in total scratching frequency within 30min in the mice of the experimental group became more significant as the concentration of action increased to 100 and 300 μ M, suggesting that the ability of isoflavan a of glycyrrhiza to suppress acute pruritus induced by SLIGRL increased with the increase in concentration. It is worth mentioning that line graphs showing the number of scratching times by time-interval statistics (see fig. 5A-C): the different concentrations of isoflavan each caused a more rapid decay of the number of scratching in the mice of the experimental group over time, whereas when the superimposed concentration of isoflavan was sufficiently high (300. mu.M), the number of scratching in the mice of the experimental group was much lower from the beginning than in the control group not administered, and the P-value calculated by analysis of variance using repeated measurements was also less than 0.01, which showed on the other side that isoflavan had indeed an inhibitory effect on acute pruritus in SLIGRL.
Test example 4 Effect of Licorice Xidine on mouse acute itching model
Selecting 24 purchased 8-10 week old (weight 20-25g, half male and female) wild type C57BL/6J mice (Sibefu (Beijing) laboratory animal science and technology Co., Ltd.), randomly dividing into 3 groups, namely a Liquirocidine high dose group (300 μ M), a medium dose group (100 μ M) and a low dose group (30 μ M), wherein each group comprises 8 mice, and removing hair on the back of the neck of the mice at least 2-3 days earlier;
the test example 3 was repeated except that 50. mu.l of physiological saline containing glycyrrhizin at different concentrations (30. mu.M, 100. mu.M, 300. mu.M) was pre-injected intradermally into the back of the right ear on the day of the official test, and after 30min, 50. mu.l of physiological saline containing 50. mu.g of SLIGRL and added with glycyrrhizin at the corresponding concentration (i.e., both SLIGRL and glycyrrhizin were contained in the physiological saline, wherein the concentrations of glycyrrhizin respectively correspond to the concentrations at the time of pre-injection, i.e., SLIGRL + glycyrrhizin) was continuously injected into the same site to induce acute pruritus.
As a result, it was found that, in the mice of the experimental group to which 30, 100 or 300 μ M glycyrrhizin was additionally added, a different degree of reduction in total scratching frequency within 30min was also observed compared to the control group to which no drug was administered (i.e., only SLIGRL was injected on the left ear side, i.e., SLIGRL + DMSO group) (fig. 6D). The difference between the 30 μ M experimental group and the control group did not reach a significant level (P ═ 0.0523), but when the treatment concentration was increased to 100 and 300 μ M, the total scratching frequency of the experimental group mice within 30min was significantly lower than that of the control group, which means that the liquiritigenin had the same effect as that of the liquiritigenin isoflavanone and was also effective in inhibiting the acute pruritus reaction induced by SLIGRL. Time-phased statistics of scratching times also yielded results similar to that of glycyrrhiza isoflavan nails (see fig. 6A-C): the number of scratching tends to decay more rapidly over time in mice of each experimental group, whereas the difference between the two groups reaches a significant level (P <0.05) when the superimposed concentration of glycyrrhizin is increased to 300 μ M. The results all prove that the Liquiritidine can also effectively inhibit acute pruritus induced by SLIGRL.
By calculating the ratio of the total scratching times of the mice in different experimental groups to the mice in the corresponding control groups within 30min after SLIGRL injection, it can be observed that the inhibition effect of the isoflavanone and the liquiritigenin is stronger and stronger along with the increase of the action concentration, and the similar dose dependence is shown (figure 7).
Considering that TRPV3 KO mice (TRPV3 knockout mice) have been reported to induce acute pruritus significantly less to SLIGRL than wild type mice, as a control on the other hand, it was also attempted to induce acute pruritus by injecting SLIGRL at the same dose into TRPV3 KO mice (purchased from Jackson laboratories (Jackson Lab), usa), and as a result, the reduction of scratching response relative to wild type mice was comparable to the reduction when high concentrations of isoflavan-a and glycitein were used. Thus: the glycyrrhiza isoflavan nail and the glycyrrhetinic acid completely antagonize TRPV3 at high concentration, thereby achieving almost the same effect of directly knocking out TRPV3 in the aspect of inhibiting SLIGRL acute pruritus.
Chronic pruritus is an important complication of many skin diseases and systemic diseases, the existing treatment means in clinic are quite lacking, and even the scratching behavior can aggravate skin injury and inflammation, so that the patients can fall into a vicious circle with more scratchy and more scratchy, and the normal life and the disease rehabilitation process of the patients are seriously influenced. Skin diseases with chronic pruritus which are common at present include: chronic eczema, Atopic Dermatitis (AD), psoriasis, xeroderma, senile pruritus, etc. Studies have shown that TRPV3 function-enhancing mutations cause mice to develop dermatitis symptoms very similar to AD; however, the newly published studies show that TRPV3 regulates the secretion of inflammatory factors such as TSLP in keratinocytes through interaction with the PAR2 receptor protein, and is involved in mediating symptoms such as chronic pruritus in AD model mice induced by calcipotriol. Therefore, the calcipotriol-induced model of atopic dermatitis was chosen as an example for assessing the ability of TRPV3 antagonist molecules to inhibit chronic pruritus under physiological conditions.
Test example 5 Effect of Glycyrrhetini flavanoid Compound on mouse model of chronic itching
Selecting 22 mice (Spibefu (Beijing) laboratory animal science and technology limited) of 8-10 weeks old (20-25 g weight, half male and female) wild type C57BL/6J, and randomly dividing into 3 groups, namely, a liquorice isoflavan group, a glycyrrhetinic group and a model group, wherein the liquorice isoflavan group, the model control group are 7 mice respectively, and the glycyrrhetinic group is 8 mice;
the model of Atopic Dermatitis (AD) was made by dissolving calcipotriol in absolute ethanol, dropping the solution of calcipotriol into the auricle at both sides of the mouse, 20. mu.l per ear, 1 time per day, using a 20. mu.l pipette at a working concentration of 100. mu.M, and continuously inducing for 7 days.
To test the effect of the compounds in inhibiting chronic pruritus by antagonizing TRPV3, treatment was performed by superimposing (with vaseline as a base) 1% by mass of licoisoflavana or glycyrrhetin plaster (i.e., glycyrrhiza isoflavana group, glycyrrhetin group) while using calcipotriol to induce AD model, and the specific operation schedule of molding and administration treatment was as shown in fig. 8: starting 5 days before formal molding, 1 per thousand of the liquorice isoflavan nail or the liquorice cetidine plaster is smeared on the auricles of the ears of the mice (about 15mg per ear) once every day; in the model group, 1 per mill of DMSO plaster is smeared on the auricle of the ears of the mouse (about 15mg of each ear) once a day; during AD molding, the liquorice isoflavan group and the liquorice cetidine group are continuously smeared after the calcium potriol is administrated for half an hour every day, and the model group is coated with vaseline matrix after the calcium potriol is administrated for half an hour every day until 7 days after molding; with recordings made and binaural pinna thickness tested on days 0, 4, and 7.
During video recording, mice are respectively placed into an observation box (15cm multiplied by 10cm) for adaptive activity for 5min, then a camera is used for video recording for 60min, attention is paid to keep the ambient environment quiet, video recording is reviewed afterwards, and scratching behaviors are counted in a time period of 5 min.
Results before AD modelling with calcipotriol formally (day 0), the total scratching times within 60min were very low for both experimental groups (glycyrrhiza isoflavan nail group, glycyrrhetinic group) and model groups, and were not significantly different (fig. 9A-B); after 4 days of model making, the mice have obvious chronic pruritus symptoms, at the moment, the total scratching times of the experimental group treated by 1 per thousand of the glycyrrhiza isoflavan nail and the glycyrrhetinic acid within 60min are only about half of that of the model group, and the differences are all significant (fig. 9C-D); after 7 days of modeling, the chronic pruritus symptoms of the mice are very serious, and the total scratching frequency of each experimental group within 60min is still lower than that of the model group, but the reduction degree of the experimental group treated by only 1 per thousand of the glycyrrhetinic acid reaches a remarkable level (fig. 9E-F). In addition, along with the appearance of AD molding process, except for chronic pruritus reaction, the inflammation of the mouse ear is continuously aggravated, which is intensively reflected by the continuous increase of the auricle thickness, as shown in figure 10, the average thickness of the mouse ear of 1 per thousand of the experimental groups of the isoflavan nail and the glycyrrhetinyl is obviously reduced compared with that of the model group on the 4 th and 7 th days, and the situation that the isoflavan nail and the glycyrrhetinyl have certain anti-inflammatory effect is prompted. It is noted that the significance of the differences in average thickness of the ears of mice in the experimental group of glycyrrhiza isoflavana compared to the model group tended to decrease over time, suggesting that the anti-inflammatory effect may be more limited and good effect could not always be ensured, compared to that of licoxidin, which is much stronger.
Test example 6 Effect of Glycyrrhiza isoflavan Compound on TRPV3 function-enhancing mutant
The glycyrrhiza isoflavane compound not only has an effect on TRPV3 wild type, but also has a blocking effect on a function enhancing mutant of TRPV3, so that the action range of the glycyrrhiza isoflavane compound is expanded.
1. Qualitative test
In previous studies it has been reported that function-enhancing mutants of TRPV3 (e.g. G573S) can induce cell death. Therefore, by using the Kit of Novozam Mut Express II Fast Mutagenesis Kit, the required site-directed mutation primers are designed according to the primer design principle as follows:
the upstream sequence: 5'-gtccatgagcatgtacagcgtcatgatccagaagg-3'
The downstream sequence: 5'-ctgtacatgctcatggactggaaaccccgcgta-3'
Plasmid pCMV6-AC-GFP-TRPV3 was point mutated according to the recommended procedures of the point mutation kit to obtain a plasmid with the G573S mutation.
Transfection was performed using the Lipofectamine 3000 transfection kit, using the protocol recommended in the kit. Transient transfection of TRPV 3G 573S mutant channel plasmid with GFP tag in HEK293T cell line, and adding antagonist ruthenium red (20 μ M), glycyrrhiza isoflavan nail (10 μ M or 20 μ M), and glycyrrhiza Citradine (10 μ M or 20 μ M) during transfection process; cell culture fluid was discarded after 12h of transfection, washed once with PBS and stained with Hoechst33342/PI apoptosis staining kit, after staining, many cells positive for PI staining could indeed be observed under a fluorescence microscope (FIG. 11), indicating massive cell death.
As can be seen from fig. 11: after the addition of the antagonist ruthenium red (20 μ M) at the same time as the transfection of the G573S mutant plasmid, the number of cells with positive PI staining became very small (see FIG. 11), indicating that it was difficult to induce cell death again once the overexpressed TRPV 3G 573S mutant channel was blocked by the antagonist;
when HEK293T cells which are added with 10 or 20 mu M of glycyrrhiza isoflavana and glycyrrhetinic acid at the same time and overexpress G573S mutant channels are subjected to PI staining, only a few cells with red fluorescent signals can be observed under a fluorescence microscope (as shown in figure 11), which indicates that the overexpressed TRPV 3G 573S mutant channels are blocked by the glycyrrhiza isoflavana and the glycyrrhetinic acid.
2. Quantitative test
In order to quantitatively test the effect of glycyrrhiza isoflavan and glycyrrhetin on TRPV 3G 573S mutant channel, TRPV 3G 573S mutant channel plasmid with GFP tag was transiently transfected in HEK293T cell line, antagonists ruthenium red (10. mu.M or 20. mu.M), glycyrrhiza isoflavan (10. mu.M or 20. mu.M), and glycyrrhetin (10. mu.M or 20. mu.M) were added during transfection, and then cell suspension mixed with the above compounds and transfection solution was seeded into 96-well plate for culture. After at least 12h of culture, the Cell Viability was characterized by luciferase Assay for ATP using the CellTiter-Glo luminescennt Cell Viability Assay kit.
When testing, 100. mu.l of mixed CellTiter-Glo test solution is added into each well, and the mixture is mixed on a shaking table for 2min to lyse cells; continuing to stand at room temperature for at least 10min to ensure the reaction is complete; and then reading by using a multifunctional microplate reader in a chemiluminescence mode.
As a result, it was found that similar to the effect of ruthenium red, the addition of 10 or 20. mu.M of both molecules simultaneously with the transfection of G573S mutant plasmid significantly increased the chemiluminescence intensity characterizing cell viability (see FIG. 12). The results of the qualitative and quantitative detection show that the isoflavan-A and the Liquiritidine have strong blocking effect on the TRPV3 function-enhancing mutant.
Example 1 Glycyrrhiza isoflavan nail ointment
Firstly, 240g of white vaseline, 160g of octadecanol and 40g of glyceryl monostearate are heated and melted in a water bath at the temperature of 80 ℃ to prepare an oil phase;
20g of sodium dodecyl sulfate, 140g of glycerol and 4g of 4% ethylparaben, and heating at 80 ℃ to dissolve the mixture in 500ml of distilled water to prepare a water phase;
slowly adding the water phase into the oil phase under stirring, condensing into emulsion matrix, adding 100g of radix Glycyrrhizae isoflavane, bottling, sterilizing, packaging, and making into ointment with 1000 pieces each containing 100mg of radix Glycyrrhizae isoflavane.
The amount of the added glycyrrhiza isoflavan nail can be 1-200g, and each prepared ointment contains 1-200mg of glycyrrhiza isoflavan nail.
Optionally replacing Glycyrrhrizae radix isoflavan with Glycyrrhrizae radix western-style injection to obtain Glycyrrhrizae radix western-style injection.
Example 2 Glycyrrhiza isoflavan nail ointment
Firstly, 300g (usually 10-500g) of white vaseline, 500g (usually 50-1000g) of paraffin, 2000g (usually 500-8000g) of liquid paraffin, 1000g (usually 100-2000g) of glyceryl monostearate and 8050 g (usually 5-100g) of span are heated and melted in a water bath at 80 ℃ to prepare an oil phase;
emulsifier OP 50g (usually 5-100g), 4% ethyl hydroxybenzoate 10g (usually 1-20g), heating at 80 deg.C and dissolving in 1000ml (usually 100-2000ml) distilled water to obtain water phase;
slowly adding the oil phase into the water phase, stirring while adding, condensing into emulsion matrix, adding 100g of radix Glycyrrhizae isoflavane, bottling, sterilizing, packaging, and making into ointment containing 1-200mg of radix Glycyrrhizae isoflavane per ointment.
The amount of the added glycyrrhiza isoflavan nail can be 1-200g, and each prepared ointment contains 1-200mg of glycyrrhiza isoflavan nail.
Optionally replacing Glycyrrhrizae radix isoflavan with Glycyrrhrizae radix western-style injection to obtain Glycyrrhrizae radix western-style injection.
Example 3 Glycyrrhiza isoflavanone ointment (preparation of oleaginous base ointment)
100g of isoflavane A, adding 3000g (usually 50-5000g) of liquid paraffin, stirring into paste, adding 5000g (usually 100-8000g) of vaseline, and grinding to uniformity. Filling, sterilizing, and making into ointment with 1000 pieces, each containing 100mg of compound Glycyrrhrizae radix isoflavane.
The amount of the added glycyrrhiza isoflavan nail can be 1-200g, and each prepared ointment contains 1-200mg of glycyrrhiza isoflavan nail.
Optionally replacing Glycyrrhrizae radix isoflavan with Glycyrrhrizae radix western-style injection to obtain Glycyrrhrizae radix western-style injection.
Example 4 Glycyrrhiza isoflavan nail ointment (preparation of aqueous base ointment)
Adding 200g (usually 30-300g) of CMC-Na into 5000ml (usually 100-8000ml) of ethanol, grinding to wet, adding 5000ml (usually 500-8000ml) of glycerol, continuously grinding to be uniform (no block), continuously adding 200ml (usually 50-300ml) of sodium benzoate aqueous solution (containing 20g (usually 5-30g) of sodium benzoate) while grinding, mixing uniformly, and swelling to obtain a water-soluble matrix; adding 100g of isoflavane A, mixing, filling and sterilizing. Making into ointment with 1000 pieces, each containing 100mg of compound Glycyrrhrizae radix isoflavane.
The amount of the added glycyrrhiza isoflavan nail can be 1-200g, and each prepared ointment contains 1-200mg of glycyrrhiza isoflavan nail.
Optionally replacing Glycyrrhrizae radix isoflavan with Glycyrrhrizae radix western-style injection to obtain Glycyrrhrizae radix western-style injection.
The above-described embodiments of the present invention are merely exemplary and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (9)
1. Application of radix Glycyrrhizae isoflavane derivative in preparing medicine or health product for preventing, relieving or/and treating pruritus is provided.
2. The use according to claim 1, wherein the glycyrrhiza isoflavan derivative is one or more of glycyrrhiza isoflavan formazan, glycyrrhetin or derivatives with 3-phenylchroman as a core, or stereoisomers and pharmaceutically acceptable salts and/or solvates thereof, preferably glycyrrhiza isoflavan formazan and glycyrrhetin.
3. The use according to claim 1 or 2, wherein the medicament consists of a glycyrrhiza isoflavan derivative and a pharmaceutically acceptable carrier.
4. Use according to claim 1 or 2, wherein the medicament is in the form of tablets, capsules, pills, powders, granules, syrups, emulsions, injections, sprays, gels, creams, cataplasms, rubber patches.
5. The use according to claim 1 or 2, wherein the purity of the glycyrrhiza isoflavan derivative is not less than 1%.
6. A medicament or health product for preventing, alleviating or/and treating pruritus is characterized by containing glycyrrhiza isoflavan derivatives.
7. The pharmaceutical or nutraceutical according to claim 6, wherein the glycyrrhiza isoflavan derivative is one or more of glycyrrhiza isoflavan formazan, glycyrrhetin or derivatives with 3-phenylchroman as core, or stereoisomers and pharmaceutically acceptable salts and/or solvates thereof, preferably glycyrrhiza isoflavan formazan, glycyrrhetin.
8. The medicament of claim 6 or 7, wherein the ratio of the weight of the glycyrrhiza isoflavan derivative to the total weight of the medicament or health product is 0.01-10: 100.
9. the medicament according to claim 6 or 7, wherein the purity of the glycyrrhiza isoflavan derivative is not less than 1%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110218633.XA CN114028384B (en) | 2021-02-24 | 2021-02-24 | Application of liquorice isoflavan derivative in preparation of drug for preventing, relieving or/and treating pruritus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110218633.XA CN114028384B (en) | 2021-02-24 | 2021-02-24 | Application of liquorice isoflavan derivative in preparation of drug for preventing, relieving or/and treating pruritus |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114028384A true CN114028384A (en) | 2022-02-11 |
CN114028384B CN114028384B (en) | 2023-05-23 |
Family
ID=80139670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110218633.XA Active CN114028384B (en) | 2021-02-24 | 2021-02-24 | Application of liquorice isoflavan derivative in preparation of drug for preventing, relieving or/and treating pruritus |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114028384B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116919965A (en) * | 2023-05-24 | 2023-10-24 | 徐州医科大学 | Application of TRPM 1 specific small molecule inhibitor ML-SI3 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103349786A (en) * | 2013-06-04 | 2013-10-16 | 北京大学第一医院 | Method for screening cutaneous pruritus treatment medicines treating TRPV3 channel protein as target |
CN105566269A (en) * | 2015-03-27 | 2016-05-11 | 北京大学 | Preparation and pharmacological effects of coumarin derivative and application of coumarin derivative to treatment on pruritus |
CN105582005A (en) * | 2015-12-11 | 2016-05-18 | 北京大学 | Novel medical application of isopentenyl isoflavone compounds in licorice roots |
CN108743580A (en) * | 2018-07-31 | 2018-11-06 | 南京道尔医药科技有限公司 | Application of the Radix Glycyrrhizae isoflavan first in preparing medicament for treatment of depression |
-
2021
- 2021-02-24 CN CN202110218633.XA patent/CN114028384B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103349786A (en) * | 2013-06-04 | 2013-10-16 | 北京大学第一医院 | Method for screening cutaneous pruritus treatment medicines treating TRPV3 channel protein as target |
CN105566269A (en) * | 2015-03-27 | 2016-05-11 | 北京大学 | Preparation and pharmacological effects of coumarin derivative and application of coumarin derivative to treatment on pruritus |
CN105582005A (en) * | 2015-12-11 | 2016-05-18 | 北京大学 | Novel medical application of isopentenyl isoflavone compounds in licorice roots |
CN108743580A (en) * | 2018-07-31 | 2018-11-06 | 南京道尔医药科技有限公司 | Application of the Radix Glycyrrhizae isoflavan first in preparing medicament for treatment of depression |
Non-Patent Citations (2)
Title |
---|
JASMIN SEIWERTH 等: "Anti-Inflammatory Effect of a Novel Topical Herbal Composition (VEL-091604) Consisting of Gentian Root, Licorice Root and Willow Bark Extract", 《PLANTA MED》 * |
张明发 等: "甘草及其有效成分的皮肤药理和临床应用", 《药物评价研究》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116919965A (en) * | 2023-05-24 | 2023-10-24 | 徐州医科大学 | Application of TRPM 1 specific small molecule inhibitor ML-SI3 |
CN116919965B (en) * | 2023-05-24 | 2024-05-17 | 徐州医科大学 | Application of TRPM 1 specific small molecule inhibitor ML-SI3 |
Also Published As
Publication number | Publication date |
---|---|
CN114028384B (en) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Antidepressant-like effects of albiflorin extracted from Radix paeoniae Alba | |
US20220226318A1 (en) | Compounds for treatment of diseases related to DUX4 expression | |
CN111278440B (en) | Method of treating amyotrophic lateral sclerosis with pridopidine | |
CA3213864A1 (en) | Dosing regimen of tradipitant | |
RU2608442C2 (en) | Use of meadowsweet (filipendula) extracts for treating and preventing chronic pain | |
CA3050700C (en) | Use of pridopidine for the treatment of fragile x syndrome | |
Kodithuwakku et al. | Anti-inflammatory and antinociceptive effects of Chinese medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis | |
JP7429942B2 (en) | Enantiomers of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (ANAVEX2-73) and their use in the treatment of Alzheimer type and other disorders regulated by sigma 1 receptors | |
BR112018013903B1 (en) | Uses of orvepitant or a composition comprising the same to treat chronic cough | |
DE60315258T2 (en) | TREATMENT OF NON-PAINTING BLADDER TROUBLESHOOTING WITH MODULATORS OF THE ALPHA 2 DELTA SUB-UNIT OF THE CALCIUM CHANNEL | |
CN114028384A (en) | Application of licorice isoflavane derivative in preparation of medicine for preventing, relieving or/and treating pruritus | |
Zhang et al. | SNS alleviates depression-like behaviors in CUMS mice by regluating dendritic spines via NCOA4-mediated ferritinophagy | |
CN105566269B (en) | Preparation, pharmacological action and the application for treating itch of coumarin derivative | |
WO2018079695A1 (en) | Inhibitor for cognitive function decline | |
CN102821760A (en) | New pharmaceutical composition suitable for treating persons affected by neurodegenerative or neurovascular diseases | |
US10842788B2 (en) | Application of levorotatory tetrahydropalmatine to the treatment of depression disorders, bipolar and related disorders, and manic episodes | |
JP2019531309A (en) | Protective effect of DMPC, DMPG, DMPC / DMPG, LYSOPG and LYSOPC against drugs that cause channel disease | |
Mishra et al. | Study of cns activities of piperine perse and its bio-enhancing effect on various drugs in experimental animal models | |
JP2012126716A (en) | Composition effective for prevention and treatment of dementia, and chinese/crude medicine preparation containing the same | |
Acquas et al. | Caffeine and the brain: An overview | |
US10568856B2 (en) | Composition for improved sleep | |
Teleuca et al. | The prospects of the use of homeopathic medicines sactus with mental disorders | |
Cazacincu et al. | The optimization of prolonged release matrix tablets with betahistine dihydrochloride-Part I | |
Fu et al. | Guhan Yangsheng Jing mitigates hippocampal neuronal pyroptotic injury and manifies learning and memory capabilities in sleep deprived mice via the NLRP3/Caspase1/GSDMD signaling pathway | |
CN100438889C (en) | Compound Chinese patent drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |